S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
Log in

NASDAQ:MNLOMenlo Therapeutics Stock Price, Forecast & News

$2.59
-0.05 (-1.89 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.42
Now: $2.59
$2.78
50-Day Range
$2.18
MA: $3.64
$5.53
52-Week Range
$1.87
Now: $2.59
$8.00
Volume469,400 shs
Average Volume567,075 shs
Market Capitalization$63.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.
Read More
Menlo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNLO
CUSIPN/A
Phone650-486-1416

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.64 million
Book Value$2.81 per share

Profitability

Net Income$-73,700,000.00

Miscellaneous

Employees43
Market Cap$63.30 million
Next Earnings Date5/7/2020 (Estimated)
OptionableNot Optionable

Receive MNLO News and Ratings via Email

Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter.


Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions

How has Menlo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Menlo Therapeutics' stock was trading at $3.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MNLO stock has decreased by 21.5% and is now trading at $2.59. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Menlo Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Menlo Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Menlo Therapeutics.

When is Menlo Therapeutics' next earnings date?

Menlo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Menlo Therapeutics.

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc (NASDAQ:MNLO) posted its quarterly earnings results on Tuesday, March, 3rd. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.06. View Menlo Therapeutics' earnings history.

What price target have analysts set for MNLO?

4 Wall Street analysts have issued 12-month price objectives for Menlo Therapeutics' shares. Their forecasts range from $8.00 to $25.00. On average, they anticipate Menlo Therapeutics' stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 382.6% from the stock's current price. View analysts' price targets for Menlo Therapeutics.

Has Menlo Therapeutics been receiving favorable news coverage?

News coverage about MNLO stock has trended very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Menlo Therapeutics earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutMenlo Therapeutics.

Are investors shorting Menlo Therapeutics?

Menlo Therapeutics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,643,000 shares, an increase of 389.2% from the February 27th total of 540,300 shares. Based on an average daily volume of 1,012,900 shares, the days-to-cover ratio is presently 2.6 days. Currently, 18.5% of the shares of the stock are short sold. View Menlo Therapeutics' Current Options Chain.

Who are some of Menlo Therapeutics' key competitors?

What other stocks do shareholders of Menlo Therapeutics own?

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the following people:
  • Mr. Steven L. Basta, Pres, CEO & Director (Age 53)
  • Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 47)
  • Dr. Mary C. Spellman, Chief Medical Officer (Age 57)
  • Dr. Paul S. Kwon M.D., Chief Scientific Officer (Age 48)
  • Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 54)

When did Menlo Therapeutics IPO?

(MNLO) raised $86 million in an IPO on Thursday, January 25th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO."

How do I buy shares of Menlo Therapeutics?

Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Menlo Therapeutics' stock price today?

One share of MNLO stock can currently be purchased for approximately $2.59.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $63.30 million and generates $10.64 million in revenue each year. The company earns $-73,700,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis. Menlo Therapeutics employs 43 workers across the globe. View additional information about Menlo Therapeutics.

What is Menlo Therapeutics' official website?

The official website for Menlo Therapeutics is http://www.menlotherapeutics.com/.

How can I contact Menlo Therapeutics?

Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected]

This page was last updated on 4/3/2020 by MarketBeat.com Staff

Featured Article: Trading on Margin

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel